J. Stern & Co. LLP Has $106.32 Million Stake in DexCom, Inc. $DXCM

J. Stern & Co. LLP lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 2,114.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,601,973 shares of the medical device company’s stock after purchasing an additional 1,529,641 shares during the quarter. J. Stern & Co. LLP’s holdings in DexCom were worth $106,323,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. CVA Family Office LLC raised its stake in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. MCF Advisors LLC bought a new position in DexCom in the fourth quarter valued at about $32,000. ORG Partners LLC boosted its holdings in DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Spire Wealth Management boosted its holdings in DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares during the last quarter. Finally, Aventura Private Wealth LLC bought a new position in DexCom during the fourth quarter worth about $43,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares in the company, valued at approximately $7,326,353. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 40,994 shares of company stock worth $2,919,022 in the last ninety days. Corporate insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on DXCM shares. BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Benchmark initiated coverage on DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price target on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $91.00 price target on shares of DexCom in a research report on Monday, June 8th. Stifel Nicolaus set a $90.00 target price on DexCom and gave the stock a “buy” rating in a research note on Friday, June 5th. Finally, Bank of America decreased their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $84.83.

DexCom Price Performance

DexCom stock opened at $73.16 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $28.23 billion, a PE ratio of 31.26, a P/E/G ratio of 1.16 and a beta of 1.45. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a 50-day moving average price of $66.59 and a two-hundred day moving average price of $67.76.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.32 earnings per share. Analysts expect that DexCom, Inc. will post 2.58 EPS for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.